Recent studies have used results on SNP association with schizophrenia (SZ) and bipolar disorder (BD) to create polygenic risk scores (PRS) discriminating non-familial unrelated patients from controls. Little is known about the role of PRS in densely affected multigenerational families. We tested PRS differences between affected SZ and BD family members from their non-affected adult relatives (NAARs) in Eastern Quebec Kindreds and from controls. We examined 1227 subjects: from 17 SZ and BD kindreds, we studied 153 patients (57 SZ, 13 schizoaffective, and 83 BD) and 180
group along with population controls. Using only a BD PRS, Fullerton et al. (2015) compared BD affected subjects and their NAARs, but only 32 SNPs were used in the PRS, the number of subjects per family was relatively small and the subjects had diverse ethnic backgrounds.
Another study tried to identify brain regions whose function may be related to BD PRS and also examined the discrimination by the BD PRS of BD patients from unaffected first-degree relative and unrelated healthy controls (Dima, de Jong, Breen, & Frangou, 2016) , but the group sizes were small. A study of Ahn, An, Shugart, and Rapoport (2016) also found that childhood-onset SZ patients had higher genetic risk scores for SZ than their healthy siblings with a SZ PRS defined from the PGC results.
As far as we can tell, no study of patients affected by SZ or BD and NAARs in multigenerational families coming from a founder population have used PRS with the thousands of risk alleles needed to achieve the best discrimination between patients and controls (Schizophrenia Working Group of the Psychiatric Genomics, 2014). Our objective was to evaluate the ability of PRS to discriminate affected adult subjects from NAARs in the Eastern Quebec Schizophrenia and Bipolar Disorder Kindreds and from non-affected adult controls.
| METHODS

| Samples and diagnosis
The sample for this study contained 333 subjects from 17 SZ and BD families of the Eastern Quebec population. A best-estimate lifetime DSM-IV diagnosis was made as outlined in previous reports (Maziade et al., 1992; Maziade et al., 1995; Roy et al., 1997) . In brief, all available information across lifetime from different sources (all medical records, family informant interviews, personal structured interview) was reviewed blindly by four research diagnosticians. The diagnoses observed for those subjects were: 57 SZ, 13 schizoaffective subjects (SAD), 83 BD which contained 68 BD I and 15 recurrent major depressive disorder (RMD), for a total of 153 affected subjects, and 180
NAARs as defined in Bureau et al. (2013) . The CARTaGENE project (Awadalla et al., 2013) provided genotype data for 894 healthy control subjects who had no medical history of SZ, SAD, or BD and RMD from the same population (Quebec City and Saguenay sampling sites).
| Ethics statement
The study was explained to each family member and a signed consent 
| Genotyping
Whole-genome SNP genotyping was made using DNA extracted from immortalized lymphocytes by affinity column (Midi prep Qiagen) for 334 familial subjects using Infinium Human OmniExpress24 Illumina microchips. One subject with a BD diagnosis was removed due to a 
| Genotype imputation
Before imputation, the phasing of our familial sample genotypes was done by Shapeit2 software (mathgen.stats.ox.ac.uk/genetics_ software/shapeit/shapeit.html) which allowed us to use the family information in the phasing process via the duoHMM algorithm (O'Connell et al., 2014) . The imputation of all common variants was then made by the Michigan Imputation Server (MIS) (imputationserver.
sph.umich.edu) based on the Haplotype reference consortium panel (McCarthy et al., 2016) . A subset of 64 SNPs that were not used in the imputation process (genotyped separately from the Illumina Omni Express chip) was used to calculate quality imputation statistics: 92% of those SNPs had an observed R-squared ≥ 0.8 and 92% had a concordance rate ≥0.95 between the imputed and observed genotypes.
We then did the imputation of all common variants for the 894 remaining control subjects by using the same process as we used for the 333 related subjects, except that the phasing was made with no family information because the controls were unrelated subjects.
| Polygenic risk scores calculation
In addition of the genomic data, we obtained results on odds ratios and p-values for the association of approximatively 10 million autosomal
SNPs with SZ from a study of the PGC (Schizophrenia Working Group of the Psychiatric Genomics, 2014) and with BD from a study of Hou et al. (2016) . Those results were used to calculate SZ and BD polygenic risk scores (PRS) for all the subjects of our study. We selected the SNPs used in the calculation of the PRS by selecting the SNPs who had pvalues for association with the diseases under 0.10 and 0.05.
We constructed two types of polygenic risk scores (PRS) for our 333 related subjects and 894 CARTaGENE control subjects, the proxy PRS and the imputation PRS. The proxy PRS was constructed with proxy SNPs on the Illumina Omni Express chip while the imputation PRS was constructed after the imputation of all common variants in the human genome from the observed genotypes (Supplementary Figure S1 ).
For the proxy PRS at threshold 0.05 and 0.10, the first step was to select the SNPs genotyped by the Illumina Omni Express chip. The last step was to make the LD pruning on the remaining SNPs with plink. The window size in SNPs used was 50 kb, the number of SNPs to shift the window at each step was 5 and the VIF threshold was 1.5. For the imputation PRS, the first step was to get a LD pruned and clumped set of SNPs. For the SZ PRS, we took the list of SNPs downloadable on the PGC's website and for the BD PRS, we made our own LD pruned and clumped data based on genotype data on our familial sample with plink.
We discarded SNPs within 250 kb and with a R-squared ≥ 0.1 with a SNP more significantly associated to BD. The second step was to select Finally, we constructed all the same PRS with the same SNPs for the 894 controls than the PRS constructed for the 333 related subjects. However, as some SNPs used in the calculation of the proxy PRS were not genotyped by the different CARTaGENE chips, we had to use imputed genotypes for those SNPs to have exactly the same SNPs in the calculation of the proxy PRS for the 894 controls.
We also constructed four supplementary PRS, namely combined SZ-BD PRS, by combining BD and SZ PRS with the corresponding SNPs of each type of PRS. The first step was to compute a value of R-square between the SNPs in the SZ PRS and the SNPs in the BD PRS. Identical
SNPs and highly correlated SNPs (R-square> = 0.8) were used only once in the calculation of the combined SZ and BD PRS (see Figure 1) . we obtained a total of 12 PRS for 1227 subjects.
| Association of PRS with diagnoses
The primary analysis involved affected subjects against NAARs using the imputation PRS with threshold 0.10, the PRS definition achieving the best discrimination between SZ cases and controls in the PGS study (Schizophrenia Working Group of the Psychiatric Genomics, 2014). The imputation PRS with threshold 0.05 and the proxy PRS were used to evaluate the sensitivity of the results to the PRS definition. The comparison of affected subjects with controls was performed as a secondary analysis. The models used to study the discrimination between affected subjects and non-affected subjects (NAARs and controls) by the different PRS were logistic models estimated by generalized estimating equations (GEEs). We used the independence correlation structure and an empirical standard error estimate robust to intra-familial correlation for all the GEEs (Zeger, Liang, & Albert, 1988) . One-sided p-values for higher risk in an affected group versus a comparison group were computed and a Bonferroni correction for multiple testing set the significance threshold to 0.05/3 = 0.0167 (SZ, BD, and all affected subjects vs. NAARs) for each PRS in the primary analysis. The analysis of each PRS was treated as a distinct replication. We used the same significance threshold for our secondary analysis (comparison with controls). We also calculated Nagelkerke R 2 with the logistic models using a binomial pseudolikelihood (i.e., assuming subjects were independent) to compare the discrimination of the affected subjects from the non-affected subjects between the different models.
| External validation of SZ and BD PRS with symptom dimensions
Psychotic, manic and depressive symptom dimensions were available for the affected subjects. Those symptoms were evaluated on 82 items of the Comprehensive Assessment of Symptoms and History (CASH) (Andreasen, Flaum, & Arndt, 1992) (0: None, 1: Questionable, 2: Mild, 3:
Moderate, 4: Marked, 5: Severe) that cover 11 dimensions, as described by Bureau, Beaulieu, Paccalet, Chagnon, and Maziade (2017) . Due to a lack of variability of certain symptom dimensions, we considered the following list of symptom dimensions for this study: delusion, thought disorder, anhedonia, apathy, mania, and depression. Two-time frames were used to rate the symptom dimensions: lifetime acute episodes and lifetime stabilized interepisode intervals. The symptom dimensions were also standardized with the empirical quantile-normal transformation.
We then calculated the mean of the standardized symptom dimension in acute episode and the standardized symptom dimension in stabilized interepisode for each symptom dimensions.
We created two distinct groups of affected subjects based on the imputation SZ and BD PRS with threshold 0.10: the "Pure" SZ and the "Pure" BD. The Pure SZ subjects were affected subjects with a high SZ PRS (SZ PRS higher than the SZ PRS median) and a small BD PRS (BD PRS smaller than the BD PRS median). The Pure BD subjects were affected subjects with a high BD PRS (BD PRS higher than the BD PRS median) and a small SZ PRS (SZ PRS smaller than the SZ PRS median).
All the medians used as threshold were calculated on affected subjects only. We then compared the mean of each standardized symptom dimension between these two groups, adjusting for the diagnosis (combining SZ and SAD) of the affected subjects in the two groups. We made this comparison by using linear mixed models with random additive genetic effects. Finally, we performed separate analyses with and without the subjects with recurrent major depressive disorder.
3 | RESULTS
| PRS calculation
The number of SNPs remaining after each step of the construction of the four proxy PRS and the four imputation PRS are shown in Supplementary Figure S1 . For all the PRS, there was a larger number of SNPs in imputation PRS compared to the proxy PRS. The number of SNPs used in the calculation of the different PRS varied from 8,397
SNPs to 21,140 SNPs for the proxy PRS and from 23,173 SNPs to 67,412 SNPs for the imputation PRS.
| Association of the SZ PRS and BD PRS with diagnoses
For this section, we focus on the results of the primary analysis using the imputation PRS with threshold 0.10 and comparisons with NAARs. 
| Correlation among the various PRS
Supplementary Table S2 showed high correlations between all the SZ PRS, and moderate correlations among the BD PRS were also found.
Correlations between the SZ PRS and the BD PRS were relatively low for all the types of PRS (Supplementary Figure S5) . These low correlations between SZ PRS and BD PRS, and the presence of SZ subjects with high BD PRS and conversely BD subjects with high SZ PRS, led us to examine the characteristics of subjects discordant for the two PRS, through the definition of the Pure SZ and Pure BD groups (see below). 
| Association of the combined SZ-BD PRS with diagnoses
| External validation of SZ and BD PRS with symptom dimensions
The different groups of Pure SZ subjects and Pure BD subjects are illustrated in Figure 3 . The Pure SZ (i.e., subjects with a high SZ PRS score and a low BD PRS score) were the 21 SZ patients and 16 BD patients located in the bottom right corner. The Pure BD subjects (i.e., subjects with a high BD PRS score and a low SZ PRS score) were the 25 BD patients and 14 SZ patients located in the upper left corner. Pure SZ and Pure BD subjects did not differ significantly on any symptom dimension (Table I and Supplementary Table S3) . However, among BD subjects, the SZ PRS predicted subjects with RMD disorder (i.e., without mania). We then repeated the analysis after excluding subjects with the RMD diagnosis, leaving 23 Pure BD and 12 Pure SZ in the BD diagnosis group, and found that the Pure SZ had a higher mean for thought disorder than the Pure BD (Table 1) , although the p-value did not reach the significance threshold of 0.0083 after Bonferroni correction for the six symptom dimensions (0.0083). Table 1 shows that the subjects with a SZ diagnosis that were also predicted SZ by the two PRS (Pure SZ) seemed to have more of psychotic symptoms than subjects with a SZ diagnosis who were predicted BD by the two PRS (Pure BD). Moreover, BD subjects who were predicted as SZ by the two PRS (Pure SZ) presented higher means for thought disorder than the BD subjects who were predicted as BD by the two PRS (Pure BD). Complementary results for the five other symptom dimensions are presented in Supplementary Table S3 .
| DISCUSSION
Our results support our hypothesis that SZ PRS and BD PRS discriminate SZ and BD subjects from their non-affected adult relatives. This has already been found for a narrower definition of BD PRS by Fullerton et al. (2015) in families with high polygenic risk load (but not in their full family sample). Our findings with PRS also showed differences between affected subjects and controls, as found in other studies (Psychiatric, 2011; Schizophrenia This commonality supports that numerous SZ risk alleles would also be associated with BD and that numerous BD risk alleles would also be associated with SZ, as shown previously in unrelated, mostly nonfamilial subjects (Consortium C-DGotPG, 2013; Purcell et al., 2009 ).
This finding motivated us to test a combined SZ-BD PRS, which showed a slightly stronger difference between affected subjects and NAARs or controls than the SZ and BD PRS. Notably, our results among the different SZ PRS were generally concordant as were our results for the different BD PRS, with a few exceptions. This is consistent with the high correlations observed among the various SZ PRS and among the various BD PRS.
When we examined symptom dimensions in patients discordant for their SZ and BD PRS, we found suggestive evidence that patients with high SZ and low BD PRS (Pure SZ) had higher thought disorder symptoms than subjects with low SZ PRS and high BD PRS (Pure BD), irrespective of diagnosis, after removing RMD disorder subjects from BD patients. This suggests that the SZ and the BD PRS may have specificity regarding the thought disorder symptoms.
Our study has strengths and limitations. A first strength is the combination of a relatively large sample size from multigenerational SZ and BD families and the utilization of a PRS built with the most recent results in term of association of risk alleles with SZ and BD (Hou et al., 2016 ; Schizophrenia Working Group of the Psychiatric Genomics, 2014) and with optimal numbers of risk alleles to compare patients to controls, which was not the case in previous studies (Dima et al. 2016; Fullerton et al., 2015) . Second, for the imputation process, we used The two first columns represent the mean of thought disorder for the patients diagnosed SZ and classified in the group of the Pure SZ and the Pure BD based on the polygenic risk scores obtained from their genotype. The two middle columns represent the mean of thought disorder for the patients diagnosed BD and classified in the group of the Pure SZ and the Pure BD. The two last columns give the Beta and the p-value given by the mixed model analysis for the factor Genotype (Pure SZ vs. Pure BD).
family information which improves the phasing of the genotypes (O'Connell et al., 2014) . Third, we used two methods for the construction of the different PRS and we obtained relatively consistent results for the two methods. A first limitation is that despite a relatively large sample from multigenerational SZ and BD families, the number of subjects remains limited, particularly when we analyzed the SZ subjects and BD subjects separately. A second limitation were the technical differences in the genotyping of the controls from CARTaGENE versus the SZ and BD familial subjects. DNA from cell lines was used for SZ and BD familial subjects while DNA from blood was used for controls. Familial subjects (SZ, BD, and unaffected relatives) and controls were genotyped on different SNP arrays. Family information was used for the imputation in familial subjects but was not available for the imputation in the controls. Finally, the proxy/ imputed status of the SNPs included in the PRS differed between familial subjects and controls (due to differences in the SNPs included on each array). Given that all SNP genotyping was done with recent highly accurate genotyping assays, and that imputation quality was found to be high, such technical differences related to genotyping would be unlikely to have a big impact. The small amplitude of differences in PRS between NAARs and controls also renders unlikely the presence of systematic differences between the familial subject and control genotypes that would impact PRS.
In conclusion, SZ and BD PRS can distinguish affected subjects from their NAARs as significantly as from controls, a result that could be improved by the combination of the SZ and BD PRS.
